An observational study in Limbal Stem Cell Deficiency, sponsored by Claris Biotherapeutics, Inc.. Recruiting at 21 sites in United States. Open to participants aged 12 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Claris Biotherapeutics, Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this non-interventional, observational study is to describe the natural history, clinical course, and management patterns of subjects with limbal stem cell deficiency (LSCD).
38 studies on the registry are indexed under Limbal Stem Cell Deficiency; 15 are open to participants now.
This study's planned enrollment of 500 is above the median of 69 across 12 observational studies indexed under Limbal Stem Cell Deficiency.
Browse Limbal Stem Cell Deficiency studies →Claris Biotherapeutics, Inc. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult and adolescent subjects with qualifying LSCD
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Other inclusion/exclusion criteria apply.
No product administration.
Other: Non-interventional
Non-interventional
Natural Progression of LSCD as Assessed by Changes in Patient Reported Outcomes
Onset or changes (worsening or improving) in vision-related quality of life and ocular symptoms as captured with the National Eye Institute Visual Function Questionnaire-25 (VFQ-25) and Ocular Surface Disease Index (OSDI) questionnaires
Time frame: Screening through Week 84
Natural Progression of LSCD as Assessed by Functional Changes (Photophobic BCVA)
Change in photophobic BCVA
Time frame: Screening through Week 84
Natural Progression of LSCD as Assessed by Functional Changes (Low-luminance BCVA)
Change in low-luminance BCVA
Time frame: Screening through Week 84
Natural Progression of LSCD as Assessed by Functional Changes (Low-contrast BCVA)
Change in low-contrast BCVA
Time frame: Screening through Week 84
Natural Progression of LSCD as Assessed by Functional Changes (Contrast Sensitivity)
Change in contrast sensitivity (Pelli-Robson)
Time frame: Screening through Week 84
Natural Progression of LSCD as Assessed by Anatomical/Structural Changes
Change in area of central cornea conjunctivalization
Time frame: Screening through Week 84
Changes that May be Correlated with LSCD as Assessed by Functional Changes (Corneal Sensitivity)
Changes (onset, improvement, or worsening) in corneal sensitivity
Time frame: Screening through Week 84
Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Corneal Topography/Tomography)
Changes (onset, improvement, or worsening) in corneal topography and/or tomography and/or densitometry
Time frame: Screening through Week 84
Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Epithelial Defect Frequency)
Changes (onset, improvement, or worsening) in epithelial defect frequency
Time frame: Screening through Week 84
Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Palisades of Vogt Crypts)
Changes (onset, improvement, or worsening) in Palisades of Vogt crypts
Time frame: Screening through Week 84
Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Epithelial and Total Corneal Thickness)
Changes (onset, improvement, or worsening) in epithelial and total corneal thickness
Time frame: Screening through Week 84
Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Pannus)
Changes (onset, improvement, or worsening) in pannus
Time frame: Screening through Week 84
Changes that May be Correlated with LSCD as Assessed by Changes Ocular and Systemic Health Outcome Measures
Changes (onset, improvement/resolution, or worsening) of an existing condition
Time frame: Screening through Week 84
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Mar 2028, 22 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Claris Biotherapeutics, Inc.